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Feasibility of an alternative, physiologic, 
individualized open-lung approach 
to high-frequency oscillatory ventilation 
in children
Pauline de Jager1, Tamara Kamp1, Sandra K. Dijkstra1, Johannes G. M. Burgerhof2, Dick G. Markhorst3, 
Martha A. Q. Curley4, Ira M. Cheifetz5 and Martin C. J. Kneyber1,6* 
Abstract 
Background: High-frequency oscillatory ventilation (HFOV) is a common but unproven management strategy in 
paediatric critical care. Oscillator settings have been traditionally guided by patient age and/or weight rather than by 
lung mechanics, thereby potentially negating any beneficial effects. We have adopted an open-lung HFOV strategy 
based on a corner frequency approach using an initial incremental–decremental mean airway pressure titration 
manoeuvre, a high frequency (8–15 Hz), and high power to initially target a proximal pressure amplitude (∆Pproximal) of 
70–90 cm  H2O, irrespective of age or weight.
Methods: We reviewed prospectively collected data on patients < 18 years of age who were managed with HFOV for 
acute respiratory failure. We measured metrics for oxygenation, ventilation, and haemodynamics as well as the use of 
sedative-analgesic medications and neuromuscular blocking agents.
Results: Data from 115 non-cardiac patients were analysed, of whom 53 had moderate-to-severe paediatric 
acute respiratory distress syndrome (PARDS). Sixteen patients (13.9%) died. Frequencies≥ 8 Hz and high ∆Pproximal 
were achieved in all patients irrespective of age or PARDS severity. Patients with severe PARDS showed the great-
est improvement in oxygenation. pH and  PaCO2 normalized in all patients. Haemodynamic parameters, cumulative 
amount of fluid challenges, and daily fluid balance did not deteriorate after transitioning to HFOV in any age or PARDS 
severity group. We observed a transient increase neuromuscular blocking agent use after switching to HFOV, but 
there was no increase in the daily cumulative amount of continuous midazolam or morphine in any age or PARDS 
severity group. No patients experienced clinically apparent barotrauma.
Conclusions: This is the first study reporting the feasibility of an alternative, individualized, physiology-based open-
lung HFOV strategy targeting high F and high ∆Pproximal. No adverse effects were observed with this strategy. Our 
findings warrant further systematic evaluation.
Keywords: Acute respiratory failure, Paediatric acute respiratory distress syndrome, High-frequency oscillatory 
ventilation, Mechanical ventilation, Paediatrics, Child, Oxygenation
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Introduction
High-frequency oscillatory ventilation (HFOV) is con-
sidered as a rescue intervention in children suffering 
from acute lung injury when conventional mechanical 
ventilation (CMV) fails [1, 2]. However, there are scarce 
paediatric scientific data supporting its use. The only pae-
diatric randomized controlled trial (RCT) that evaluated 
the effects of HFOV on patient outcome was published in 
1994 and found no differences in mortality rates between 
HFOV and CMV [3]. Continued use of HFOV in pae-
diatrics became even more controversial following two 
negative clinical trials in adult ARDS and two recent pae-
diatric observational reports failing to show any benefit 
of HFOV on patient outcome [4–7]. Gupta et al. reported 
increased mortality and prolonged duration of mechani-
cal ventilation associated with early or late HFOV in a 
database analysis study using propensity score match-
ing, although there were serious methodological issues 
related to this study [6, 8, 9]. Bateman and co-workers 
performed a post hoc analysis of paediatric patients 
enrolled into a large protocolized paediatric sedation trial 
using propensity matching with clinically relevant vari-
ables [7]. When patients managed with early HFOV were 
compared with those supported with late HFOV or CMV, 
mortality was unchanged, but duration of mechanical 
ventilation was prolonged in the early HFOV group.
It remains unclear whether the outcomes of these 
studies confirm that HFOV is not beneficial, or even 
harmful, or that patient outcome was determined by 
the oscillator management strategy [10–12]. Most pae-
diatric HFOV studies make no mention of recruitment 
manoeuvres (RM) and reported frequencies (F) in the 
range of 5–8 Hz. Yet, optimizing lung volume by means 
of a RM seems physiologically necessary when transition-
ing to HFOV to recruit collapsed, atelectatic lung units 
being exposed to larger, potentially more injurious pres-
sure swings [13]. Furthermore, use of low oscillatory F is 
not in line with the concept of the corner frequency (Fc) 
[2]. Fc is the F at which the pressure cost of ventilation is 
the lowest, in other words the F that is the least injuri-
ous to the lung [14]. In disease conditions with reduced 
respiratory system compliance (Crs), such as ARDS, Fc 
is increased indicating that the highest oscillatory F that 
still allows for adequate ventilation might be preferable.
We started using an individualized, physiology-driven 
strategy to HFOV as an alternative mode of ventila-
tion for PARDS rather than the more traditional size/
age-based approach as a rescue intervention. Our strat-
egy is centred on an open-lung concept using an initial 
staircase incremental–decremental mean airway pres-
sure (mPaw) titration manoeuvre, a high F (12 Hz), and 
high power to initially target a proximal pressure ampli-
tude (∆Pproximal) of 70–90 cm  H2O, irrespective of age or 
weight. Here, we report our first experiences with this 
alternative approach to HFOV in a heterogeneous group 
of patients with moderate-to-severe acute lung injury. 
We studied the feasibility of our strategy and examined 
the level and time course of metrics for oxygenation and 
ventilation and hemodynamic parameters as well as the 




This study was designed as a retrospective review of 
prospectively collected data between January 2013 and 
December 2015.
Patients
Included were all children younger than 18  years of 
age managed with HFOV for acute respiratory fail-
ure originating from any cause, defined by acute onset, 
presence of ≥ 1 infiltrate on chest radiograph,  PaO2/
FIO2 < 300  mmHg and PEEP ≥ 5  cm  H2O. Patients with 
status asthmaticus, upper airway disorders, and under-
lying (congenital) cardiac anomalies were excluded. All 
patients had body weight within appropriate for age.
Data collection
Demographic, physiological, laboratory and ventilator 
parameters were manually extracted from the patient’s 
medical record. Disease severity was assessed by the 
Pediatric RIsk of Mortality (PRISM) III 24-h score. We 
applied the paediatric ARDS (PARDS) definition to iden-
tify patients with ARDS [15]. All consecutive PICU chest 
radiograph images were reviewed by a paediatric radiolo-
gist to determine the presence or absence of pulmonary 
infiltrates.
Variable definition and calculation
Physiological and laboratory data included heart rate, 
invasively measured arterial systolic, mean and diastolic 
blood pressure (mABP), central venous pressure (if a 
central line was in  situ), and transcutaneous measured 
oxygen saturation  (SpO2). These variables were continu-
ously monitored using a Philips MP70 Intellivue moni-
tor (Philips Medical Systems, Best, the Netherlands) and 
documented hourly by the bedside nurse. Although the 
frequency of arterial blood sampling was completed at the 
discretion of the attending physician, typically, arterial 
blood gases and lactate are measured at least every 6  h 
daily in the early phase of the oscillatory trajectory unless 
the clinical condition of the patient warranted more fre-
quent analysis (Radiometer, Brønshøj, Denmark). Venti-
lator parameters for conventional mechanical ventilation 
(CMV) included PIP, mean airway pressure (mPaw), 
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positive end-expiratory pressure (PEEP), expiratory tidal 
volume (Vte), and  FiO2; for HFOV, these included mPaw, 
F, ∆P and  FiO2. Vte was measured near the Y-piece of the 
endotracheal tube in patients < 10  kg (VarFlex™, Vyaire, 
Yorba Linda, CA, USA). These data were documented 
hourly. The PF ratio and oxygenation index (OI: mPaw 
*  FiO2 * 100)/PaO2) were computed using concurrent 
blood gas and ventilator data.
To study haemodynamics, we analysed the daily 
cumulative fluid intake and number of fluid boluses 
administered. A daily vasoactive inotrope score (VIS) 
was calculated to describe the need for vasoactive sup-
port [16]. The non-respiratory Pediatric Logistic Organ 
Dysfunction (PELOD) 2 score was calculated daily to 
describe organ dysfunction [17]. The use of neuromuscu-
lar blocking agents (NMBAs) was noted as well as total 
daily cumulative dosage of sedatives and analgesic drugs. 
The use of NMBA, sedation and analgesia were managed 
using a unit-based clinical algorithm.
CMV protocol
Patients were managed per a unit-based algorithm. This 
algorithm prescribes the use of a time-cycled, pres-
sure-limited ventilation mode (pressure control (PC)/
assist control (AC) in children < 12  months or PC/syn-
chronized intermittent mandatory ventilation (SIMV) 
in children ≥ 12  months) in children with acute lung 
injury. Expiratory tidal volume (Vte) is measured near 
the Y-piece of the endotracheal tube (ETT) in chil-
dren < 10  kg (VarFlex™, Vyaire, Mettawa, Ill, USA). We 
target PIP < 30–32 cm  H2O and maximum Vte 5–8 mL/
kg actual bodyweight in all patients. Initial PEEP at the 
start of CMV is 4–6 cm  H2O in all patients, adjustments 
are dictated by the  FiO2 at the discretion of the attend-
ing physician. We do not use the ARDS Network PEEP/
FiO2 grid or lung volume optimization manoeuvres such 
as staircase PEEP titration or sustained inflation during 
CMV [18]. Mandatory breath rate is dictated by underly-
ing respiratory mechanics and age to maintain pH within 
target range; the flow-time scalar is carefully observed to 
prevent auto-PEEP. The maximum I/E ratio is 1:1. The 
amount of pressure support in the PC/SIMV mode is cal-
culated by PIP minus PEEP.
HFOV protocol
Patients are oscillated per a unit-based algorithm that 
defines HFOV criteria, recruitment manoeuvre (RM), 
and titration of HFOV settings according to the evolv-
ing physiologic needs of each patient (SensorMedics 
3100; Vyaire, Yorba Linda, CA, USA). Transitioning to 
HFOV is performed when peak inspiratory pressure 
(PIP) > 28–32 cm  H2O, PEEP > 8 cm  H2O,  FiO2 > 0.60, and 
oxygenation index (OI) increases on three consecutive 
1-hour measurements despite increasing PEEP and using 
neuromuscular blockade. A specific OI or mPaw thresh-
old is not used to initiate HFOV. Vt was not measured 
when the patient was on HFOV.
The following starting HFOV settings are used: F 
12  Hz, mPaw 3  cm  H2O above mPaw on CMV, ∆Pproxi-
mal 70–90  cm  H2O, inspiratory time 33%, and bias flow 
20–40 L/min, irrespective of age or bodyweight. Imme-
diately after switching to HFOV, we perform an individu-
alized staircase incremental–decremental mPaw titration 
to find the optimal initial mPaw on the deflation limb of 
the pressure–volume relation (Figs. 1, 2). In brief, imme-
diately after transitioning to HFOV, we perform an indi-
vidualized staircase incremental–decremental mPaw 
titration to find the optimal initial mPaw on the deflation 
limb of the pressure–volume relation (Fig.  1). First, we 
increase the mPaw 2 cm  H2O every 3–5 min while simul-
taneously observing the  SpO2 (as proxy for lung volume) 
and mean ABP until no further improvement in  SpO2 
and/or decrease in mean ABP occurs during two con-
secutive increments. This allows us to identify the onset 
of lung recruitment (i.e. increase in  SpO2,  mPawrecruitment) 
and the onset of lung overdistension  (mPawhyperinflation). 
If during the RM the  SpO2 exceeds 97%, we reduce 
 FiO2 and continue the RM. Next, we decrease the 
mPaw by 2 cm  H2O every 3–5 min until  SpO2 decreases 
 (mPawderecruitment) during two consecutive decrements. 










mPawDerecruitment (↔/↓SpO2 ; ↓mABP)
(↓SpO2)
(↓↓↓ SpO2)
Fig. 1 Graphical simplification of the stepwise incremental–
decremental mPaw titration when switching to HFOV. The red line 
represents the inspiratory limb of the pressure volume loop, whereas 
the green line represents de deflation limb. The mPaw is increased by 
2 cmH2O every 3–5 min until no further improvement in  SpO2 and/
or decrease in mean ABP occurs during two consecutive increments 
(identifying  mPawrecruitment and  mPawhyperinflation). Then, the mPaw 
is decreased by  cmH2O every 3–5 min until  SpO2 decreased 
 (mPawderecruitment) during two consecutive decrements. The RM was 
repeated to  mPawhyperinflation with setting the “optimal” mPaw + 2 
cm  H2O above  mPawderecruitment. mPaw mean airway pressure;  SpO2 
transcutaneously measured oxygen saturation; mABP mean arterial 
blood pressure
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“optimal” mPaw + 2  cm  H2O above  mPawderecruitment. 
During the RM, oscillations are continued.
The RM is discontinued in the event of bradycardia 
and/or refractory hypotension (i.e. > 20% decrease in 
mABP for > 5  min). Chest radiographs are not routinely 
taken after the RM. During ongoing support, the mPaw 
is actively decreased by 2  cm  H2O if  FiO2 < 0.40–0.50 
and  SpO2 is within target range. F is decreased by 0.5–
1.0 Hz (min 8 Hz) when the pH is below target range and 
increased by 0.5–1 Hz if the pH rises above target range. 
We decrease the power by 10% if hypocapnia occurs at F 
15 Hz. The ETT cuff is routinely inflated.
Failure of HFOV is defined by the inability to wean 
either the mPaw or the  FiO2 over the first 24  h follow-
ing start of HFOV or if there is a worsening of the oxy-
genation index despite “maximum” HFOV settings. If 
a patient meets these criteria, he will be cannulated for 
extra-corporeal life support (ECLS).
Targets of oxygenation and ventilation in all patients
FiO2 is adjusted to maintain  SpO2 88–92%. Unless dic-
tated by the clinical condition, permissive hypercapnia 
is allowed targeting pH ≥ 7.20 irrespective of  PaCO2. 
Transcutaneous  CO2 monitoring is not used.
Supportive care in all ventilated patients
All patients were ventilated in the supine position and 
received continuous intravenous infusion of analgesic-
sedative drugs, including midazolam and morphine. 
The bedside nurse titrated the analgesic-sedative drugs 
guided by the heart rate and pupils (for patients on neu-
romuscular blockade) or by the Comfort B score (for 
non-paralyzed patients) [19]. Hemodynamic manage-
ment of ventilated patients included targeting a fluid 
nil balance via fluid restriction (± 75% of normal fluid 
intake) and intravenous diuretic therapy (continuous 
intravenous administration of furosemide). The decision 
to prone a patient is at the discretion of the attending 
physician.
Study endpoints
The primary endpoint of this study was feasibility of our 
protocol (in each patient, defined as maintaining F ≥ 8 Hz 
and ∆Pproximal 70–90  cmH2O as function of disease sever-
ity. Secondary endpoints included the level and trajectory 
of metrics for oxygenation and ventilation as function 
of disease severity and the level and trajectory of hemo-
dynamic parameters, occurrence of new air leak, daily 
cumulative dosage of sedative-analgesic drugs and use 
of NMBA, and level and time course of the non-respir-
atory PELOD-2 as function of age. The latter was chosen 
because the current approach to HFOV calls for oscilla-
tor settings dictated by age and/or weight.
Statistical analysis
Continuous data are presented as median and 25–75 
interquartile range (IQR) since assumptions of normality 
were not always satisfied. Categorical data are presented 
as percentage (%) of total. When comparisons between 
groups were made, continuous data were analysed using 
Fig. 2 HFOV stepwise incremental–decremental mPaw titration
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the Kruskal–Wallis test, and the Chi-square test with 
Yates continuity correction was used to analyse cat-
egorical data. Generalized linear model analyses were 
performed to analyse the effects of PARDS severity, age, 
survival status and time as well as the interaction between 
time and age or PARDS severity on all study endpoints as 
these parameters are repeated measurements. All statisti-
cal analyses were performed using SPSS for Mac (IBM, 




During the 3-year study period, 1787 patients were 
mechanically ventilated > 24  h (58.2% of all admitted 
patients). One hundred and forty-eight (8.3%) of those 
patients were supported on HFOV. Eleven patients 
were excluded from analysis because they were oscil-
lated for status asthmaticus (N = 6) or upper airway 
disorders (N = 3) or had an incomplete dataset (N = 2). 
Twenty-two (16.1%) patients were excluded due to con-
genital heart lesions. Thus, data from 115 patients were 
eligible for analysis.
Table  1 summarizes baseline patient characteristics 
and last ventilator settings prior to HFOV stratified 
by PARDS severity. The three groups were well-bal-
anced except for the PRISM-III 24-h score. The major-
ity of patients had direct lung injury. No patients were 
proned. Two patients were cannulated for ECMO: 
one with moderate PARDS and the other with severe 
PARDS. Sixteen (13.9%) patients died during their 
PICU stay; mortality was the highest (33.3%) in severe 
PARDS patients. Eight patients died because treatment 
was redirected based on the underlying disorder (e.g. 
chronic lung disease (N = 4), neuromuscular disorders 
(N = 1) or haemato-oncologic disorder (N = 3); seven 
patients died of multiple organ failure. Except for one 
Table 1 Study population characteristics and last ventilator settings prior to high-frequency oscillatory ventilation
Data are depicted as median (25–75 interquartile range) or percentage (%) of total
PARDS pediatric acute respiratory distress syndrome; PRISM pediatric risk of mortality, PHT pulmonary hypertension, PICU pediatric intensive care unit, PARDS pediatric 
acute respiratory distress syndrome, PIP peak inspiratory pressure, PEEP positive end-expiratory pressure, Vt tidal volume, CMV conventional mechanical ventilation, 
HFOV high-frequency oscillatory ventilation
*p < 0.05
Variable No or mild PARDS (N = 62) Moderate PARDS (N = 29) Severe PARDS (N = 24)
Age (months) 4.5 (2.0–12.5) 5.0 (2.0–24.5) 6.0 (1.8–20.23)
 0–12 months (%) 75.8 69.0 66.7
 13–60 months (%) 14.5 20.7 20.8
 > 60 months (%) 9.7 10.3 12.5
Male (%) 54.8 48.3 45.8
Weight (kg) 7.0 (4.5–10.8) 5.5 (3.8–11.5) 6.9 (4.1–11.3)
PRISM-III 24 h* 6.0 (3.0–8.0) 6.0 (3.0–6.5) 12.5 (8.23–37.78)
Admission diagnosis (%)
 Pulmonary 85.5 79.3 79.2
 PHT 1.6 0 8.3
 Acute liver failure 0 0 8.3
 Pancreatitis 1.6 0 0
 Sepsis 9.7 13.8 4.2
 Post-operative 1.6 6.9 0
PICU stay (days) 10.0 (7–17) 10.0 (8.0–15.0) 12.5 (8.3–37.8)
PICU mortality (%)* 6.5 10.3 33.3
Last ventilator settings on conventional mechanical ventilation before switch to HFOV
PIP  (cmH2O) 29 (27–32) 28 (26–30) 29 (27–33)
mPaw  (cmH2O) 15 (14–16) 16 (14–17) 17 (15–19)
PEEP  (cmH2O) 7.0 (6.0–8.1) 7.8 (6.5–8.1) 7.4 (6.7–9.9)
Vtexp (mL/kg) 6.3 (5.7–7.5) 7.0 (6.3–7.9) 7.0 (6.2–8.0)
FiO2* 0.61 (0.50–0.99) 0.75 (0.55–0.90) 0.99 (0.75–1.0)
 Time on CMV before start HFOV (h) 10 (3–14) 10 (5–17) 11 (3–16)
 Total length of HFOV run (h) 91 (66–123) 102 (67–149) 134 (69–224)
 Total length of CMV run after HFOV (h) 72 (28–160) 73 (12–169) 77 (22–172)
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drowning victim, all patients had serious co-morbidi-
ties. No patient died from refractory hypoxemia.
Level and time course of F, ∆Pproximal and mPaw as function 
of severity
Figure 3 graphically depicts oscillator settings over time 
stratified by PARDS severity. It was possible to main-
tain F ≥ 8  Hz and ∆Pproximal within the target range of 
70–90  cmH2O, irrespective of age or PARDS severity 
throughout the study period. After the RM, there was 
no significant difference in mPaw between the three 
PARDS severity groups, although children > 60  months 
required significantly higher mPaw (p < 0.001). The mPaw 
decreased significantly over time (p < 0.001). The rate of 
decrease in mPaw over time was not affected by PARDS 
severity or age. None of the patients suffered from clini-
cally apparent barotrauma.
Effect on metrics for oxygenation and ventilation 
as function of severity
Figure  4 shows the level and time course of oxygena-
tion and ventilation stratified per PARDS severity. The 
increase in OI immediately after the RM seen in all 
three groups was caused by an increase in mPaw. The OI 
decreased in all three groups over time, but this decrease 
was only significant (p < 0.01) in the severe PARDS group. 
Similarly, the  PaO2/FiO2 ratio improved significantly over 
time in the severe PARDS group (p < 0.01). The  PaCO2 
and pH significantly improved in the first 6  h follow-
ing the RM (p < 0.01), but, thereafter, there was no fur-
ther change. These changes were similar when stratified 
by age or PARDS severity, except for the normalization 
of pH which was more rapid in patients with no/mild 
PARDS (p < 0.01).
Effect on haemodynamics, fluid management, and organ 
function as function of age
We did not observe a negative effect over time on HR, 
mABP, central venous pressure (CVP), or arterial lac-
tate when patients were either stratified by age or 
PARDS severity (Fig.  5). At the same time, the number 
of patients who required vasoactive support increased 
significantly over time (Fig.  6). Yet, the median vasoac-
tive score did not increase significantly over time, sug-
gesting no increase in haemodynamic instability. More 
children > 60  months were administered a fluid bolus 
on the second (p = 0.027) and third day (p = 0.022) 
of HFOV than younger children, but the cumulative 
amount of fluid challenges was not significantly different 
between the age groups (Fig. 6). All of these observations 
remained the same when stratified for PARDS severity.
The median non-respiratory PELOD-2 score for 
patients on CMV was 2 (25–75 IQR 0–3). This score 
remained consistent throughout the first 3  days after 
transition to HFOV (day 1: median 0 (0–2); day 2: median 
2 (0–3); day 3: median 2 (0–3) and was not influenced by 
of age or PARDS severity.
Use of sedative‑analgesic drugs and NMBA
We observed a significant increase in NMBA administra-
tion in the first 48 h (p < 0.01) of HFOV use, after which 
NMBA use significantly decreased (p < 0.01) from day 2 
to day 3 (Fig. 7). There was no significant change in the 
mean midazolam (mg/kg/hr) or morphine (mcg/kg/hr) 
dosage in any of the age or PARDS severity groups over 
time (Fig.  6). Children < 12  months required less mida-
zolam than older children when on CMV and during the 
first 3  days of HFOV (Fig.  7). All of these observations 
remained the same when stratified for PARDS severity.
Discussion
To the best of our knowledge, this is the first study 
reporting that an individualized, physiology-based open-
lung HFOV approach characterized by high F and high 
initial ∆Pproximal in paediatric patients is feasible and does 
not impair gas exchange or haemodynamics, irrespective 
of age or PARDS severity.
HFOV is traditionally considered as rescue therapy in 
case of refractory hypoxemia, although there are some 
paediatric reports supporting earlier use [6, 20]. Our 
liberal criteria for transitioning to HFOV may be inter-
preted as lack of full optimization of CMV. Indeed, we 
employ HFOV early in the disease trajectory when a 
patient meets pre-defined criteria rather than using it as 
a rescue intervention as proposed in international con-
sensus statements in order to prevent ventilator settings 
from becoming toxic [21, 22]. Inherently, the number of 
patients managed with HFOV might be higher than in 
comparable centres including a wider patient spectrum 
not limited to only patients with severe lung disease. Our 
liberal use may therefore explain the observed differences 
in improvement in OI and  PaO2/FiO2 ratio between 
PARDS severity strata. The greatest improvement in 
these metrics was observed in patients with severe 
PARDS, confirming previous observations [20].
Importantly, our study was not designed to examine 
superiority of HFOV over CMV. At the same time, when 
interpreting our results, it cannot be ruled out that, at 
least in a proportion of patients in our population, similar 
effects on oxygenation and ventilation could have been 
achieved if a (ultra-)lung protective ventilation strategy 
(i.e., lower Vt in combination with RM) continued, and 
NMBA administration, prone positioning, and/or higher 
PEEP were used, potentially in combination. It must be 
acknowledged that the best strategy to optimize CMV 
in children with severe PARDS remains uncertain [22]. 
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Fig. 3 Level and time course of achieved, frequency (F) (upper panel), proximal pressure amplitude ∆Pproximal (middle panel) and mean airway 
pressure (mPaw) (lower panel)during the first 72 h of high-frequency oscillatory ventilation (HFOV), stratified by paediatric acute respiratory distress 
syndrome (PARDS) severity (N = 62 children no/mild PARDS, N = 29 children moderate PARDS, N = 24 children severe PARDS). “Start” is the first 
measurement immediately after the recruitment manoeuvre. Data are depicted as median (25–75 interquartile range). *p < 0.05
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Recommendations for ventilator management and use of 
(non-)pulmonary-specific ancillary treatments in PARDS 
have been made, but these are largely based on expert 
opinion rather than scientific evidence [21, 23, 24]. Pae-
diatric observational studies have reported use of higher 
levels of PEEP in PARDS than in our cohort, although 
it is common among the paediatric critical care com-
munity to tolerate higher  FiO2 [25–29]. To date, there is 
no specific PEEP strategy shown to be beneficial nor are 
there RCT data demonstrating that higher PEEP is bet-
ter than lower PEEP in PARDS, although there are some 
suggestions that lower PEEP in PARDS may be associated 
with increased mortality [29]. We also do not know the 
optimal Vt in (severe) PARDS [30]. To date, prone posi-
tioning has not been shown to improve patient outcome 
in PARDS, although this may also be explained by not 
restricting its use to severe PARDS [31]. Short-term use 
of NMBA early in the course of MV has been shown to 
improve outcome in adults with ARDS, but this remains 
unclear in paediatrics [32]. Thus, when it comes to 
paediatric MV, many unknowns remain [33]. Our study 
underscores the need for systematic testing our HFOV 
approach on patient outcome. This can only be done in a 
well-designed RCT.
Although our approach to HFOV may not be consid-
ered novel, it is not uniformly used in children [20, 34–
37]. It is more custom to set F and ∆Pproximal according to 
age, mPaw, and observation of chest wiggle [2, 20]. How-
ever, such an approach ignores the respiratory system 
mechanics of the underlying disorder. Furthermore, a 
RM after switching to HFOV is not routinely performed. 
We have adopted a physiology-based and individualized 
approach to HFOV that: a) makes use of a high F that 
allows for sufficient gas exchange and a high initial ∆Pprox-
imal with a fixed power setting, and b) a staircase incre-
mental–decremental mPaw titration aimed at finding the 
lowest mPaw on the deflation limb of the P–V loop after 
switching to HFOV. The rationale behind choosing the 
highest possible F is based on the concept of the corner 
frequency (Fc), which is influenced by the resistance and 
Fig. 4 Level and time course of the oxygenation index (OI) (upper left panel),  PaO2/FiO2 ratio (upper right panel),  PaCO2 (lower right panel) and 
pH (upper left panel) during the last 6 h of conventional mechanical ventilation (CMV) and the first 72 h of high-frequency oscillatory ventilation 
(HFOV), stratified by paediatric acute respiratory distress syndrome (PARDS) severity (N = 62 children no/mild PARDS, N = 29 children moderate 
PARDS, N = 24 children severe PARDS). “Start” is the first measurement immediately after the recruitment manoeuvre. Data are depicted as median 
(25–75 interquartile range). *p < 0.05
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compliance of the respiratory system [14]. Fc identifies 
the point of the lowest pressure cost of ventilation, i.e. 
the point that should be the least injurious to the lung. Fc 
is increased when there is reduced Crs, suggesting target-
ing F ≥ 8 Hz [2, 14]. Our data show that we were able to 
achieve F > 8 Hz, irrespective of age or severity of PARDS. 
We did not find impaired  CO2 elimination despite these 
higher F. Despite the “high” initial ∆Pproximal,  PaCO2 and 
pH levels normalized within 6  hours after transitioning 
to HFOV, especially in patients with moderate or severe 
PARDS. Although it cannot be ruled out that normaliza-
tion of the pH was also partially due to our liberal use of 
furosemide, our data also suggest that even higher F may 
be used to accept higher  PaCO2. We arbitrarily choose 
the initial ∆Pproximal not to exceed 90 cm  H2O as higher 
values may theoretically expose the proximal airways to 
injurious pressures. Reassuringly, dampening of the pres-
sure swings among the endotracheal tube is much greater 
when high F is used, thereby diminishing the likelihood 
of proximal airway injury [38].
We always perform a lung optimization manoeuvre 
after switching to HFOV to optimize end-expiratory 
lung volume (EELV) as the  PaO2 is linearly correlated 
with EELV [39]. Aside from optimizing lung volume to 
improve oxygenation, pressure oscillations are less damp-
ened in regions with poor compliance, thereby causing 
larger pressure swings [13]. One group of investigators 
found that a stepwise mPaw increase produced the great-
est increase in lung volume and resolution of atelecta-
sis compared with a 20-s sustained dynamic inflation 
(either once or repeated 6 times) or a standard approach 
(i.e. random setting of mPaw) in a neonatal lamb model 
[40]. We have adopted such a stepwise increase–decrease 
mPaw titration as a RM strategy. This allows us to indi-
vidualize the mPaw setting and oscillate on the defla-
tion limb of the P–V loop where there is less continuous 
recruitment and decruitment of alveoli [41]. Nonetheless, 
there is a need for comparing various types of RM for 
determining optimal EELV as the best RM in HFOV still 
needs to be identified. Furthermore, there appeared to be 
Fig. 5 Level and time course of hemodynamic parameters including heart rate (upper left panel), mean arteria blood pressure (upper right panel), 
central venous pressure (lower left panel) and blood lactate (lower right panel) during the last 6 h of conventional mechanical ventilation and the 
subsequent first 72 h of high-frequency oscillatory ventilation, stratified by age group (N = 83 children ≤ 12 months, N = 20 children 13–60 months 
and N = 12 children ≥ 61 months). “Start” is the first measurement immediately after the recruitment manoeuvre. Data are depicted as median 
(25-75 interquartile range). *p < 0.05
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a slow decrease in mPaw during the first 3 days after start 
of HFOV. This could mean that we did not wean HFOV 
aggressively enough, calling for a better protocolization 
of HFOV weaning instead of a gradual reduction of the 
mPaw when oxygenation was satisfactorily.
Although the number of patients put on vasoactive 
drugs increased over time, the vasoactive score (which 
includes dosages of vasoactive drugs) did not increase. 
Furthermore, the cumulative amount of fluid boluses 
remained low in our patient population. This suggests 
that there was no haemodynamic instability in our 
study population despite the delivery of a higher mPaw. 
We did note an increase in NMBA use during the first 
48 h of HFOV, especially in children > 60 months, possi-
bly reflecting work of breathing in these patients when 
Fig. 6 Level and time course of the cumulative amount of fluid boluses in mL/kg (upper left panel), vasoactive score (middle left panel) and the 
cumulative fluid balance in mL/kg (lower left panel), and the percentage of patients who received fluid boluses per day (upper right panel) and 
patients on vasoactive support per day (lower right panel), stratified by age group (N = 83 children ≤ 12 months, N = 20 children 13–60 months 
and N = 12 children ≥ 61 months). Continuous data are depicted as median (25-75 interquartile range) and categorical data as  % of total. CMV 
conventional mechanical ventilation. *p < 0.05
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Fig. 7 Percentage of patients who were on neuromuscular blocking agents (NMBA) (upper panel), mean midazolam dose (mg/kg/hour) (middle 
panel) and mean morphine dose (mcg/kg/hour) (lower panel) stratified by age group (N = 83 children ≤ 12 months, N = 20 children 13–60 months 
and N = 12 children ≥ 61 months). Continuous data are depicted as median (25–75 interquartile range) and categorical data as  % of total. CMV 
conventional mechanical ventilation. *p < 0.05
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breathing spontaneously due to the fixed bias flow of 
HFOV [42].
A key strength of this study is that we used a protocol-
ized approach to paediatric HFOV in terms of patient 
selection and management, taking disease trajectory 
into account. This has not been previously reported. At 
the same time, there are limitations that should be con-
sidered. Although we describe one of the largest cohorts 
of paediatric HFOV patients, our study represents a sin-
gle-centre experience with a liberal use of HFOV thereby 
including a subgroup of patients with less severe disease 
[2]. Furthermore, practice variability may have influenced 
our findings, but this is inherent to the study design and 
can only be overcome by a RCT [43]. Last, from a theo-
retical perspective, HFOV seems to be a suitable mode 
for lung-protective ventilation (LPV). The effect of our 
alternative approach on the development of ventilator-
induced lung injury (VILI) cannot be deducted from the 
present study and warrants further investigations. Our 
approach is currently being tested in a 2-by-2 factorial 
randomized controlled trial comparing the effects of ven-
tilation strategy (CMV vs. HFOV) with or without prone 
positioning on patient outcome (www.prosp ect-netwo 
rk.org).
Conclusion
In summary, we report the feasibility in terms of oxy-
genation, ventilation, and haemodynamics of using an 
alternative, individualized, physiology-based open-lung 
approach to HFOV that targets high F and high ∆Pproxi-
mal. Further research including multisite dissemination 
and systematic evaluation compared to CMV on both 
short- and long-term outcomes in paediatric practice is 
warranted.
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